Stay updated with breaking news from Arjun Surya. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Noida (Uttar Pradesh) [India], January 4 (ANI/PRNewswire): Curadev Pharma has created a Clinical Advisory Group (CAG) comprising eminent oncologists to provide guidance in the design and execution of immune-oncology clinical trials with CRD3874, its lead non-nucleoside, allosteric small molecule STING agonist
NOIDA, UP, Jan 4: Curadev Pharma has created a Clinical Advisory Group (CAG) comprising eminent oncologists to provide guidance in the design and execution of immune-oncology clinical trials with CRD3874, its lead non-nucleoside, allosteric small molecule STING agonist. Curadev recently received permission from the US FDA to commence FIH trials with systemically administered CRD3874 in patients with advanced/metastatic solid cancers. Dr Arjun Surya, CEO and CSO of Curadev said that, “We are honored to work with such an esteemed group […]
/PRNewswire/ -- Curadev has created a Clinical Advisory Group (CAG) comprising of eminent oncologists to provide guidance in the design and execution of...
/PRNewswire/ -- Curadev has created a Clinical Advisory Group (CAG) comprising of eminent oncologists to provide guidance in the design and execution of...
Boston (Massachusetts) [US]/ Noida (Uttar Pradesh) [India], December 6 (ANI/PRNewswire): Curadev Pharma, a small molecule drug discovery and development company focused on the generation of novel therapeutics for the treatment of intractable diseases such as cancer has received a Study May Proceed letter from the United States Food and Drug Administration (FDA) to begin a Phase 1 study of its lead STING agonist CRD3874 in advanced/metastatic solid cancers. The study will be performed at a leading US cancer center. Successful clearance of tumors by the immune system requires the action of Type ...